Innovent Biologics Inc. (6IB)

Overview

Innovent Biologics, Inc. is an innovative biopharmaceutical company focusing on developing and commercializing a broad range of monoclonal antibodies and other therapeutic drug assets. Their primary focus areas include oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases. With its foundation laid in 2011, Innovent Biologics has been dedicated to addressing the unmet medical needs in the People's Republic of China. Headquartered in Suzhou, the company has established a strong footing in the healthcare industry through its extensive product portfolio and ongoing research and development efforts.

Products and Services

Innovent Biologics provides an extensive array of products and services aimed at improving patient care and treatment outcomes. Here is a closer look at their offerings:

• Tyvyt: A human anti-PD-1 monoclonal antibody designed for cancer treatment.
• BYVASDA: A fully-human anti-VEGF monoclonal antibody aimed at inhibiting angiogenesis in various diseases.
• HALPRYZA: A recombinant chimeric murine/human anti-CD20 monoclonal antibody for treating hematologic malignancies.
• SULINNO: A fully-human antiTNF-a monoclonal antibody, used in autoimmune diseases like rheumatoid arthritis.
• Pemazyre: A selective FGFR inhibitor that targets specific fibroblast growth factor receptors involved in cancer development.
• Olverembatinib: A novel BCR-ABL tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
• Cyramza: A VEGF receptor 2 antagonist that plays a role in cancer treatment by inhibiting tumor angiogenesis.
• Retsevmo: A selective and potent RET kinase inhibitor used in treating cancers with RET mutations.
• In addition to marketed products, Innovent Biologics has an expansive pipeline of developing treatments, including:
• IBI-326: A fully-human BCMA CAR T-cell therapy targeting multiple myeloma.
• IBI-376: An oral inhibitor of PI3Kd that holds potential in treating hematologic malignancies.
• IBI-351: A KRASG12C inhibitor being developed for specific types of cancer.
• IBI-344: Targets silencing 1/TRK tyrosine kinase in cancer treatments.
• IBI-126: An ADC targeting CEACAM5 for colorectal cancer treatment.
• IBI-306: A novel monoclonal antibody against proprotein convertase subtilisin/kexin type 9 enzyme, potential in treating hypercholesterolemia.
• IBI-362: A glucagon-like peptide-1 receptor/glucagon receptor dual agonist for diabetes management.
• IBI-112: A novel long-acting anti-IL-23 for autoimmune diseases.
• The company also focuses on novel immunotherapy and targeted therapy options, including IBI-110 (novel anti-LAG3), IBI-939 (novel anti-TIGIT), and others aiming to enhance oncology treatment modalities.
• Furthermore, Innovent offers distribution services for pharmaceutical products, alongside providing consultation, and advanced research and development services to foster innovation and address diverse therapeutic areas.